Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 83

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 83
---
 a written opinion, dated August 4, 2025, to the effect that, as of such date and based upon and subject to the factors and assumptions set forth in its written opinion, the Merger Consideration of           
 $28.00 in cash per share of STAAR common stock to be received by the STAAR stockholders pursuant to the Merger Agreement was fair, from a financial point of view, to such holders. For more information, see the section of this proxy statement titled 
 “—Opinion of STAAR’s Financial Advisor” (the full text of the written opinion of Citi, dated August 4, 2025, which sets forth, among other things, the assumptions made, procedures followed, matters considered and                                     
 limitations on the review undertaken in connection with Citi’s opinion, is attached as Annex B to this proxy statement and is incorporated herein by reference).                                                                                         |

-50-

| • |     | Potential Benefits to Patients and Surgeons. The Board considered that STAAR, as a subsidiary of Alcon                                                                                                                                            
 (and indirect subsidiary of Alcon Inc.), would have access to the advantages provided by Alcon Inc.’s size and operational experience, including with respect to additional access to capital and marketing, and the resulting ability to provide 
 STAAR’s products to a greater number of surgeons and patients.                                                                                                                                                                                    |

The Board also considered a variety of risks and other potentially negative factors in its consideration of the Merger Agreement and the Merger, including the following:

| • |     | the fact that consummation of the Merger depends on the satisfaction or waiver of certain conditions which are                                 
 outside of STAAR’s control, and the risk that one or more of such conditions could fail to be satisfied or waived on a timely basis or at all; |

| • |     | the costs involved in connection with negotiating and entering into the Merger Agreement and consummating the                                                                                                                     
 Merger, and the substantial time and effort of management required to consummate the Merger and related disruptions to the operation of STAAR’s business (including certain costs and expenses if the Merger is not consummated); |

| • |     | the risk that the expiration or termination of the waiting period under the HSR Act or other required regulatory                                                                                                                              
 approvals, which are required for the consummation of the Merger, may not be obtained or that regulators may require divestitures or other remedies, and the fact that Alcon’s commitment to agree to any